Indo Us Bio-Tech Limited (NSE:INDOUS)
India · Delayed Price · Currency is INR 145.00
-4.80 (-3.20%)
Feb 19, 2026, 3:30 PM IST
Indo Us Bio-Tech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 1,178 | 1,038 | 728.36 | 617.45 | 500.59 | 401.1 |
Revenue | 1,178 | 1,038 | 728.36 | 617.45 | 500.59 | 401.1 |
Revenue Growth (YoY) | 36.63% | 42.56% | 17.96% | 23.34% | 24.80% | 0.88% |
Cost of Revenue | 834.52 | 698.44 | 466.39 | 433.94 | 343.51 | 242.87 |
Gross Profit | 343.47 | 339.95 | 261.97 | 183.5 | 157.08 | 158.23 |
Selling, General & Admin | 42.05 | 39.74 | 39.67 | 31.48 | 25.53 | 16.13 |
Other Operating Expenses | 116.94 | 109.73 | 111.64 | 58.05 | 62.09 | 88.32 |
Operating Expenses | 170.96 | 160.45 | 159.32 | 97.79 | 92.09 | 107.04 |
Operating Income | 172.51 | 179.49 | 102.66 | 85.71 | 64.99 | 51.2 |
Interest Expense | -18.48 | -14.36 | -14.1 | -11.24 | -11.45 | -11.22 |
Interest & Investment Income | 0.7 | 0.7 | 0.12 | - | 0.03 | 0.02 |
Other Non Operating Income (Expenses) | -0.52 | -0.52 | -0.7 | -0.6 | -0.46 | -0.58 |
EBT Excluding Unusual Items | 154.21 | 165.31 | 87.98 | 73.87 | 53.11 | 39.41 |
Gain (Loss) on Sale of Assets | - | - | -0.04 | - | - | -0.12 |
Pretax Income | 154.21 | 165.31 | 87.94 | 73.87 | 53.11 | 39.29 |
Income Tax Expense | 5.85 | 2.63 | 5.53 | 1.46 | 2.48 | -9.71 |
Net Income | 148.36 | 162.67 | 82.41 | 72.4 | 50.63 | 49 |
Net Income to Common | 148.36 | 162.67 | 82.41 | 72.4 | 50.63 | 49 |
Net Income Growth | 13.19% | 97.41% | 13.81% | 43.00% | 3.34% | 93.30% |
Shares Outstanding (Basic) | 20 | 20 | 20 | 19 | 12 | 15 |
Shares Outstanding (Diluted) | 20 | 20 | 20 | 19 | 12 | 15 |
Shares Change (YoY) | -0.04% | - | 3.95% | 57.60% | -15.96% | - |
EPS (Basic) | 7.39 | 8.11 | 4.11 | 3.75 | 4.14 | 3.36 |
EPS (Diluted) | 7.39 | 8.11 | 4.11 | 3.75 | 4.13 | 3.36 |
EPS Growth | 13.32% | 97.41% | 9.49% | -9.22% | 22.97% | 93.19% |
Free Cash Flow | - | 5.57 | -3.89 | -12.97 | -12.64 | -17.95 |
Free Cash Flow Per Share | - | 0.28 | -0.19 | -0.67 | -1.03 | -1.23 |
Dividend Per Share | - | 0.250 | - | - | 0.125 | - |
Gross Margin | 29.16% | 32.74% | 35.97% | 29.72% | 31.38% | 39.45% |
Operating Margin | 14.64% | 17.29% | 14.09% | 13.88% | 12.98% | 12.76% |
Profit Margin | 12.59% | 15.67% | 11.31% | 11.73% | 10.12% | 12.22% |
Free Cash Flow Margin | - | 0.54% | -0.53% | -2.10% | -2.52% | -4.48% |
EBITDA | 185.72 | 190.47 | 110.66 | 93.97 | 69.45 | 53.79 |
EBITDA Margin | 15.77% | 18.34% | 15.19% | 15.22% | 13.87% | 13.41% |
D&A For EBITDA | 13.21 | 10.98 | 8 | 8.26 | 4.46 | 2.59 |
EBIT | 172.51 | 179.49 | 102.66 | 85.71 | 64.99 | 51.2 |
EBIT Margin | 14.64% | 17.29% | 14.09% | 13.88% | 12.98% | 12.76% |
Effective Tax Rate | 3.79% | 1.59% | 6.29% | 1.98% | 4.67% | - |
Revenue as Reported | 1,180 | 1,040 | 731.55 | 617.66 | 502.41 | 401.53 |
Advertising Expenses | - | 0.44 | 0.26 | 0.06 | 0.22 | 1.19 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.